Premium
Review editorial: Prevention of tuberculosis in resource‐poor countries with increasing access to highly active antiretroviral treatment
Author(s) -
Apers Ludwig,
Lynen Lut,
Worodria William,
Colebunders Robert
Publication year - 2005
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2005.01516.x
Subject(s) - tuberculosis , medicine , human immunodeficiency virus (hiv) , isoniazid , developing country , antiretroviral treatment , antiretroviral therapy , tb treatment , intensive care medicine , immunology , disease , environmental health , viral load , pathology , economic growth , economics
Summary The administration of isoniazid (INH) has been proposed, evaluated and implemented to prevent tuberculosis (TB) disease among patients who are infected with the human immunodeficiency virus (HIV). This strategy has been developed in communities where TB is highly endemic and at a time when antiretroviral (ARV) treatment was not, or was rarely available. Although INH prevention programmes were somewhat pushed to the background due to the worldwide advocacy for ARV drugs, prevention of TB remains of paramount importance. The dual HIV–TB infection poses problems, not only for the individual and his/her clinician but also for the programme manager. We review various aspects of TB preventive treatment in countries with a high prevalence of HIV–TB co‐infection and limited resources but with increasing access to ARV treatment.